Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Fatma Paksoy TURKOZ"'
Autor:
Ayse Gok Durnali, Fatma Paksoy Turkoz, Fisun Ardic Yukruk, Saadet Tokluoglu, Omer Kamil Yazici, Ayse Demirci, Oznur Bal, Selay Gundogdu Buyukbas, Onur Esbah, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0152621 (2016)
Osteosarcomas with lung metastases are rather heterogenous group. We aimed to evaluate the clinicopathological characteristics and outcomes of osteosarcoma patients with lung metastases and to compare the synchronous and metachronous lung metastatic
Externí odkaz:
https://doaj.org/article/4e2e68daa8ca4237b11d37b65b9ed04e
Autor:
Arife Ulas, Fatma Paksoy Turkoz, Kamile Silay, Saadet Tokluoglu, Nilufer Avci, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114471 (2014)
We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival.The study retrospectively r
Externí odkaz:
https://doaj.org/article/6032908549874f0f9cf78544de607693
Autor:
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukbiricik, Serkan Menekse, Eyyüp Cavdar, Akın Ozturk, Esma Türkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Çağrı Yildirim, Başak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilanci, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:865-875
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dfec0cbcbdd9f35f252256f8357168
https://doi.org/10.1007/s00432-022-03984-5
https://doi.org/10.1007/s00432-022-03984-5
Autor:
Erhan Gokmen, Ozkan Alan, Gul Basaran, Serdar Turhal, Ozgur Tanriverdi, Yesim Eralp, Burcak Karaca, Semra Paydas, Fatma Paksoy Turkoz, Burcu Çakar, Sevgi Topcu, Gulhan Ipek Deniz, Bulent Karabulut, Seyda Gunduz, Osman Kostek, Taner Korkmaz, Umut Demirci, Sema Sezgin Goksu
Publikováno v:
Cancer Research. 80:P5-11
Background: Ribociclib combined with endocrine therapy (ET) have demonstrated efficacy in patients with hormone receptor (HR) positive advanced breast cancer (ABC) who experienced progression during prior ET. However, there are scarce data chemo-endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a18cbf7d094af11a0281bc8c35ee0c0
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
Autor:
Pınar Gürsoy, Ali Murat Tatlı, Dilek Erdem, Erdem Goker, Emir Çelik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atçı, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akagündüz, Sevinç Ballı, Ahmet Demirkazık, Fatıh Selcukbiricik, Serkan Menekşe, Eyyup Cavdar, Akın Öztürk, Esma Türkmen Bekmez, Serdal Turhal, Saadettin Kılıçkap, Hasan Çağrı Yıldırım, Başak Oyan, Asude Aksoy, Fatma Paksoy TURKOZ, Engin Kut, Nuran Katgı, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilancı, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC).Materials and Methods We retrospectively evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::329a68f8f25bf40e2889df2b77c8165a
https://doi.org/10.21203/rs.3.rs-1125056/v1
https://doi.org/10.21203/rs.3.rs-1125056/v1
Autor:
Mehmet Artac, Ozgur Tanriverdi, Osman Kostek, Ahmet Dirican, Özge Keskin, Nail Paksoy, Ali Alkan, Müge Sönmez, Mustafa Yildirim, Şeyda Gündüz, Zuhat Urakci, Ahmet Taner Sümbül, Semra Paydas, Kerem Oruc, Deniz Tural, Birol Yildiz, Ali Osman Kaya, Burcu Çakar, Meltem Ekenel, Fatih Selcukbiricik, Irem Bilgetekin, Fatma Paksoy Turkoz, Yuksel Urun, Mustafa Erman, Meltem Selam, Nail Özhan, Ömer Fatih Ölmez, Halil Taskaynatan, Saadettin Kilickap, Elif Atag, Selami Bayram, Deniz Tataroğlu Özyükseler, Dilek Erdem, Sabri Güncan, Tugba Basoglu, Mehmet Ali Nahit Sendur, Hasan Şenol Coşkun
Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab was modest. In the current st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad0808c1ae34df687e136a5aa5ec7ca
https://avesis.deu.edu.tr/publication/details/8d62a86a-0e4f-4339-9426-b0070cd55957/oai
https://avesis.deu.edu.tr/publication/details/8d62a86a-0e4f-4339-9426-b0070cd55957/oai
Autor:
Ahmet Taner Sümbül, Osman Kostek, Deniz Tural, Fatma Paksoy Turkoz, Şeyda Gündüz, Mehmet Artac, Ömer Fatih Ölmez, Mustafa Yildirim, Dilek Erdem, Ali Osman Kaya, Yuksel Urun, Meltem Ekenel, Birol Yildiz, Ali Alkan, Emre Akar, Nail Özhan, Halil Taskaynatan, Özge Keskin, Mehmet Ali Nahit Sendur, Deniz Tataroğlu Özyükseler, Zuhat Urakci, Nail Paksoy, Ozgur Tanriverdi, Sabri Güncan, Ugur Yilmaz, Irem Bilgetekin, Elif Atag, Kerem Oruc, Mustafa Erman, Meltem Selam, Hasan Şenol Coşkun, Ahmet Dirican, Müge Sönmez, Tugba Basoglu, Selami Bayram, Burcu Çakar, Fatih Selcukbiricik, Semra Paydas, Saadettin Kilickap
[No abstract available]
Amer Soc Clin Oncol
Amer Soc Clin Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc593e73ea82bc330c89132a0963f04
https://doi.org/10.1016/j.euf.2020.09.010
https://doi.org/10.1016/j.euf.2020.09.010
Autor:
Özlem Yapıcıer, Fatma Paksoy Turkoz, Mert Mestanoglu, Ozge Yabas Kiziloglu, Ozgun Melike Totuk Gedar
Publikováno v:
Turkish Journal of Ophthalmology
Türk Oftalmoloji Dergisi, Vol 49, Iss 3, Pp 168-170 (2019)
Türk Oftalmoloji Dergisi, Vol 49, Iss 3, Pp 168-170 (2019)
A 63-year-old woman with metastatic breast carcinoma presented to the ophthalmology clinic with diplopia and right abduction deficit. Magnetic resonance imaging showed isolated enlargement of the right medial rectus muscle. Biopsy of the enlarged mus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb61d16ba42a45c8baf0336acb6994dc
https://pubmed.ncbi.nlm.nih.gov/31245980
https://pubmed.ncbi.nlm.nih.gov/31245980
Autor:
Birol Yildiz, Mehmet Ali Nahit Sendur, Ugur Yilmaz, Osman Kostek, Meltem Ekenel, Burcu Çakar, Fatih Selcukbiricik, Ahmet Taner Sümbül, Selami Bayram, Deniz Tural, Fatma Paksoy Turkoz, Irem Bilgetekin, Kerem Oruc, Emre Akar, Mehmet Artac, Ömer Fatih Ölmez, Nail Özhan, Hasan Şenol Coşkun, Mustafa Erman, Özge Keskin
Publikováno v:
Journal of Clinical Oncology. 39:409-409
409 Background: In the current study, we evaluated whether the response first-line chemotherapy could impact atezolizumab benefit in terms of response rate and overall survival in patients with metastatic urothelial carcinoma. Methods: In this study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f675e8dcf114840d0d66811712938516
https://doi.org/10.1200/jco.2021.39.6_suppl.409
https://doi.org/10.1200/jco.2021.39.6_suppl.409
Autor:
Fatma Paksoy Turkoz, Emre Akar, Ömer Fatih Ölmez, Özge Keskin, Mehmet Artac, Burcu Çakar, Osman Kostek, Fatih Selcukbiricik, Nail Paksoy, Selami Bayram, Kerem Oruc, Ahmet Taner Sümbül, Deniz Tural, Irem Bilgetekin, Nail Özhan, Saadettin Kilickap, Mustafa Erman, Birol Yildiz, Ugur Yilmaz, Hasan Şenol Coşkun
Publikováno v:
Journal of Clinical Oncology. 38:451-451
451 Background: Anti-tumor activity and manageable safety profile of atezolizumab (ATZ) has been demonstrated in the previous clinical trials in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma. In this study, we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f486427ab2a392ce34f56186bec799
https://doi.org/10.1200/jco.2020.38.6_suppl.451
https://doi.org/10.1200/jco.2020.38.6_suppl.451